Helsinki-based clinical-stage cancer immunotherapy developer Tilt Biotherapeutics has secured an additional €6.2m in funding from Lifeline Ventures and other private investors.
Lifeline in €6.2m round for Tilt Biotherapeutics
Most Popular
Helsinki-based clinical-stage cancer immunotherapy developer Tilt Biotherapeutics has secured an additional €6.2m in funding from Lifeline Ventures and other private investors.